Purpose of review: Before this study was done, there was a difference of opinion concerning whether intraocular pressure (IOP) was involved in producing optic nerve damage when there was glaucomatous damage to the optic nerve and characteristic visual field loss, even though the IOP was in the statistically normal range. This article reviews the findings of a collaborative study aimed at finding the answer to this question.
Recent findings: The level of pressure influences the course of normal tension glaucoma, as evidenced by a slower rate of incident visual field loss in cases with 30% or more lowering of intraocular pressure. The rate of progression without treatment is highly variable, but often slow enough that half of the patients have no progression in 5 years. A faster rate occurs in women, in patients with migraine headaches, and in the presence of disc hemorrhages. Some patients may experience greater benefit from lowering of IOP than others, but further research is needed to be able to identify those most likely to benefit.
Summary: As a group, patients with normal tension glaucoma benefit from lowering of IOP. Variable rate of deterioration, as well as lack of progression in a substantial number in 5 years, suggest that treatment should be individualized according to the stage of disease and rate of progression. Traits that help predict risk and rate of progression and response to treatment are beginning to become known and, when fully known, will help guide management decisions.
Cerovski B, Popović Suić S, Bujger Z, Miljenka T, Cerovski J. Cerovski B, et al. Acta Med Croatica. 2005;59(2):123-8. Acta Med Croatica. 2005. PMID: 15909886 Review. Croatian.
[No authors listed] [No authors listed] Am J Ophthalmol. 1998 Oct;126(4):487-97. doi: 10.1016/s0002-9394(98)00223-2. Am J Ophthalmol. 1998. PMID: 9780093 Clinical Trial.
Nakazawa T. Nakazawa T. Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194. Nippon Ganka Gakkai Zasshi. 2015. PMID: 25854109 Review. Japanese.
De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, Ritch R. De Moraes CG, et al. Arch Ophthalmol. 2011 May;129(5):562-8. doi: 10.1001/archophthalmol.2011.72. Arch Ophthalmol. 2011. PMID: 21555607
Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Anderson DR, et al. Am J Ophthalmol. 2003 Nov;136(5):820-9. doi: 10.1016/s0002-9394(03)00478-1. Am J Ophthalmol. 2003. PMID: 14597032 Clinical Trial.
Bacharach J, Doan LV, Stephens KG, Usner DW, Kothe AC, Katz LJ, Navratil T. Bacharach J, et al. Ophthalmol Ther. 2024 Sep;13(9):2357-2367. doi: 10.1007/s40123-024-00992-1. Epub 2024 Jul 10. Ophthalmol Ther. 2024. PMID: 38985408 Free PMC article.
Gebert M, Heimbucher J, Gsell VK, Keimer K, Dillinger AE, Tamm ER. Gebert M, et al. Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):48. doi: 10.1167/iovs.65.1.48. Invest Ophthalmol Vis Sci. 2024. PMID: 38294803 Free PMC article.
Song WK, Lee A, Yoon J, Kim KE, Kook MS. Song WK, et al. Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):30. doi: 10.1167/iovs.65.1.30. Invest Ophthalmol Vis Sci. 2024. PMID: 38231526 Free PMC article.
Aswin PR, Mohan N, Sundar B, Ponnat AK, Radhakrishnan S, Krishnadas SR, Schehlein E. Aswin PR, et al. Indian J Ophthalmol. 2024 Mar 1;72(3):439-446. doi: 10.4103/IJO.IJO_2317_23. Epub 2024 Jan 8. Indian J Ophthalmol. 2024. PMID: 38189457 Free PMC article.
Böhm EW, Buonfiglio F, Voigt AM, Bachmann P, Safi T, Pfeiffer N, Gericke A. Böhm EW, et al. Redox Biol. 2023 Dec;68:102967. doi: 10.1016/j.redox.2023.102967. Epub 2023 Nov 18. Redox Biol. 2023. PMID: 38006824 Free PMC article. Review.